European Commission approves Boey as the first short duration neurotoxin

The European Commission approved Boey (trenibotulinumtoxinE) on July 17, 2026, for the temporary improvement of moderate to severe glabellar lines in adults, introducing a completely new clinical timeline to the aesthetic market. Developed by Allergan Aesthetics, Boey is the first approved botulinum neurotoxin serotype E, a formulation that works faster and wears off much sooner than traditional serotype A products like Botox Cosmetic.

For European clinics across all 30 European Economic Area countries, this approval establishes a new category of injectable treatment. Unlike existing toxins that take days to show results and last for months, Boey onset occurs as early as eight hours after injection, and the clinical effects typically resolve within two to three weeks. The regulatory milestone follows a previous approval by Health Canada in June 2026.

This rapid-onset, short-duration profile alters how clinicians can approach patient consultations. While traditional toxins remain the standard for long-term maintenance, Boey provides a tool for patients who want immediate results for an upcoming event, or those who are hesitant to commit to months of muscle relaxation. It also offers a low-risk entry point for first-time patients who want to trial the look of a neurotoxin without the three-to-four-month commitment. Clinicians should monitor how Allergan rolls out training and commercial availability in Europe to assess how this fast-acting option might fit alongside their existing neurotoxin offerings.

Source: AbbVie / Allergan Aesthetics, https://news.abbvie.com/2026-07-17-Allergan-Aesthetics,-an-AbbVie-Company,-Receives-European-Commission-Approval-for-Boey-R-trenibotulinumtoxinE-the-First-and-Only-Rapid-Onset,-Short-Duration-Neurotoxin-for-the-Temporary-Improvement-of-Frown-Lines